Varseta-M varsetatug masetecan Updated Nov 8
The next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.
- Phase 1 dose expansion data showed promising 20-32% response rates and median PFS of 6.8-7.1 months in heavily pretreated late-line mCRC, outperforming standard-of-care options.
- FDA granted Fast Track Designation in August 2026, which enables more frequent agency interactions and potential accelerated approval pathways.
- Varseta-M is the only EpCAM-directed ADC in clinical development, targeting a broadly expressed tumor antigen with a differentiated Probody masking technology designed to reduce off-tumor toxicity.
- Phase 1 data is still early; the 20-32% response rate comes from a small, non-randomized expansion cohort and may not replicate in larger trials.
- High-grade diarrhea is a known adverse event for topoisomerase-1 inhibitor ADCs and could limit tolerability or require dose modifications.
- The stock trades near its 52-week low of $2.11, reflecting skepticism about whether early data will translate into a registrational program.